Index

Note: Page numbers of article titles are in **boldface** type.

A

Acupuncture/acupressure
  in food-borne illness management, 564
AIDS
  food-borne diseases in patients with, 622–623
Antibiotic(s). See Antimicrobial agents
Antiemetics
  in food-borne illness management, 564
Antihistamines
  in food-borne illness management, 564
Antimicrobial agents
  *Clostridium difficile* associated with, 678
  in food-borne illness management, 565–570
    *Campylobacter*-related, 567
    *Cryptosporidium*-related, 570
    EHEC–related, 567, 570
    *Entamoeba histolytica*–related, 570
    enteroaggregative Shiga toxin–producing *E. coli* 0104:H4–related, 570
    *Giardia*-related, 570
    *Salmonella*-related, 565–567
    *Shigella*-related, 567
  in HUS patients, 590
  resistance to
    in emerging trends in food-borne diseases, 524
Antimotility agents
  in food-borne illness management, 562–563
Antispasmodics
  in food-borne illness management, 563
Arthritis
  reactive
    food-borne infections and, 606
Autoimmune disorders
  food-borne infections and, 606–607
Autoimmune thyroid disease
  food-borne infections and, 607

B

Bismuth salts
  in food-borne illness management, 563
Bowel dysfunction
  chronic
    food-borne infections and, 600–606
C

Campylobacter spp.
  food-borne illnesses related to
treatment of
  antimicrobial agents in, 567

Cancer
  food-borne diseases in patients with, 623–624

Children
  food-borne diseases in, 622

Clostridium difficile
  animal reservoirs for, 678–679
  antibiotics and, 678
  diseases associated with
    severity increase over time, 677–678
  in foods
    future aspects, 683
    hospital meals, 681
    infections due to
      mechanisms of, 677
    meat isolates, 679
    occurrence of, 679–682
    poultry isolates, 679–681
    ready-to-eat foods, 681
    suggestions for addressing, 682–683
  transmission of, 675–685
    asymptomatic carriers and gut biota, 677
    bacterium in, 676
    introduction, 675
    person-to-person, 676
    physiology of, 676–677
    temperature-related, 676–677
    virulent-types, 681
  in HUS patients
    treatment of, 591
    toxins A and B and, 677

Cryptosporidium spp.
  food-borne illnesses related to
treatment of
  antimicrobial agents in, 570

Culture-independent methods
  in food-borne illness diagnosis, 548–549

D

Dialysis
  in HUS patients
    peritonitis related to
      treatment of, 591

Diphenoxylate/atropine
  in food-borne illness management, 563
Dopamine antagonists
in food-borne illness management, 564

E

EAEC. See Enteroaggregative *Escherichia coli* (EAEC)
Eculizumab
for HUS patients, 591
EHEC. See Enterohemorrhagic *Escherichia coli* (EHEC)
Elderly
food-borne diseases in, 621–622
*Entamoeba histolytica*
food-borne illnesses related to
  treatment of
  antimicrobial agents in, 570
Enteroaggregative *Escherichia coli* (EAEC), 635–636
pathogenesis of, 636
treatment of, 636–638
virulence features of, 636
Enteroaggregative Shiga toxin–producing *E. coli* 0104:H4. See also Shiga toxin–producing *Escherichia coli* (STEC)
food-borne illnesses related to
  treatment of
  antimicrobial agents in, 570
Enterohemorrhagic *Escherichia coli* (EHEC)
clinical presentation of, 584
food-borne illnesses related to
  treatment of
  antimicrobial agents in, 567, 570
management of, 584–592
  initial, 585
  phase-specific considerations in, 585–590
    phase 1: patient in incubation period, 585
    phase 2: patient has nonbloody diarrhea, 585, 588
    phase 3: patient has bloody diarrhea, 588–589
    phase 4: patient has HUS, 589
    phase 5: patient has oligoanuric HUS, 589–590
  non-0157:H7
    vs. *E. coli* 0157:H7
diagnosis and comparative outcomes, 578–583
  STEC and, 632
  virulence features of, 634
Enterohemorrhagic *Escherichia coli* (EHEC) 0157:H7 infections
clinical course of, 633
diagnosis of, 633–634
treatment of, 635
*Escherichia coli*
diverse pathotypes of, 632
enterohemorrhagic. See Enterohemorrhagic *Escherichia coli* (EHEC)
Shiga toxin–producing. See Shiga toxin–producing *Escherichia coli* (STEC)
Escherichia coli 0157:H7
vs. non-0157:H7 EHEC
diagnosis and comparative outcomes, 578–583

F
Feeding
in food-borne illness management, 561–562
Food(s)
Clostridium difficile in
transmission of, 675–685. See also Clostridium difficile, in foods, transmission of
Food-borne disease(s). See also specific types and Food-borne infections
assessment of
patient evaluation in, 555–558
in Australia, 691–692
in China, 691
diagnosis of, 535–554
assessment in, 536–537
introduction, 536
ova and parasite examination in, 550–551
patient selection for testing, 542–543
PFGE in, 550
reporting and surveillance in, 537, 542
specimens to test in, 543–545
tests to order in, 546–549
culture-independent methods, 548–549
stool culture, 546–548
stool lactoferrin, 546
white blood cells in stool, 546
toxin detection in, 549–550
emerging trends in, 517–533
antimicrobial resistance–related, 524
described, 517–518
future directions in, 527–530
critical role of specialist in infectious diseases, 530
new culture-independent diagnostic tests, 527–528
new food vehicles, 528–530
new pathogens, 528–530
multidrug-resistant Salmonella and ground turkey, 525
pathogen subtyping in
critical role of, 526–527
recent surveillance trends, 521–524
Salmonella and peanut butter, 525–526
significance of multistate food-borne outbreaks, 525
in Europe, 691
global movement of food and people, 687–693
contributing factors, 687–688
impact of global food supply chain in, 692–693
scale of, 688
historical background of
agricultural revolution, 504–505
early civilizations, 505–512
  technology, 506–509
  trade, 509–511
  travel, 511–512
prehistory, 502–503
iatrogenic high-risk populations and, 617–629
  food-handling practices, 624–626
  introduction, 617–618
physiologic defenses, 618–620
  breakdown of mucosal barrier function, 619–620
  intestinal mucosal barrier, 618–619
  translocation of pathogens, 620
vulnerability factors, 620–624
  age-related immune deficiency, 621–622
  AIDS, 622–623
  cancer, 623–624
  pregnancy, 624
  transplant recipients, 623–624
multistate outbreaks of
  significance of, 525
pathogens causing, 538–539
perspectives in, 501–515
specific food–related
  analyses of, 519–521
treatment of, 555–576
  antimicrobial agents in, 565–570. See also Antimicrobial agents, in food-borne illness
  management
  complications of, 571
  introduction, 555
  long-term recommendations, 571
nonpharmacologic, 558–562
  feeding, 561–562
  infection control and public health considerations, 562
  micronutrients, 560–561
  ORT, 560
  probiotics, 562
outcome of
  evaluation of, 571
pharmacologic, 562–565
  antiemetics, 564
  antimiility agents, 562–563
  antispasmodics, 563
  bismuth salts, 563
  for noninfectious/toxin-mediated food poisoning, 564–565
  resistance to, 571
in U.S., 688–691
  impact of globalization on, 693
Food-borne illness. See also Food-borne infections; specific types and Food-borne disease(s)
Food-borne infections. See also specific types and Food-borne disease(s)
  clinical syndromes of, 540–541
Food-borne (continued)
  factors contributing to, 624–626
  long-term consequences of, 599–616
    autoimmune disorders, 606–607
    chronic bowel and gastrointestinal dysfunction, 600–606
    introduction, 599–600
    neurologic dysfunction, 607–608
    renal failure, 608–610
    types of, 602–605
  prevalence of, 599–600
  public health burden of, 518–519
Food-handling practices
  in avoiding food-borne infections and diseases, 624–626
Food poisoning
  noninfectious/toxin-mediated
    treatment for, 564–565

G
Gastrointestinal dysfunction
  chronic
    food-borne infections and, 600–606
Giardia spp.
  food-borne illnesses related to
    treatment of
      antimicrobial agents in, 570
Ginger
  in food-borne illness management, 564
Graves disease
  food-borne infections and, 607
Guillain-Barré syndrome
  food-borne infections and, 606–607

H
Hemolytic uremic syndrome (HUS)
  Clostridium difficile in patients with
    treatment of, 591
EHEC and
    management of, 589
  food-borne infections and, 609
German STEC 0104:H4 outbreak of 2011 and
  infectious complications related to
    independent of EHEC, 590–592
management of
  antibiotics in, 590
  postinfectious decolonization in, 591–592
oligoanuric
  EHEC and
    management of, 589–590
5-HT₃ receptor antagonists
in food-borne illness management, 564

Human norovirus (NoV), 651–674
  classification of, 652–653
  contamination and infection from
    prevention of, 660–667
      vaccines in, 661–667. See also Vaccine(s), against human NoV
detection methods, 658–660
epidemiology of, 655–656
genome organization in, 653–654
host susceptibility to, 652–653
introduction, 652
prevalence of, 652
recent outbreaks of, 656–658
research related to
  challenges of, 654–655
  structure of, 653–654
  transmission of, 655–656
  viral proteins in, 653–654
HUS. See Hemolytic uremic syndrome (HUS)

I

Immune suppression
  pregnancy-related
    food-borne diseases and, 624
Infection(s). See also specific types
  food-borne. See Food-borne infections
  STEC. See Shiga toxin–producing Escherichia coli (STEC) infections
Inflammatory bowel disease
  food-borne infections and, 601, 606
Intestinal mucosal barrier
  as physiologic defense against food-borne diseases in iatrogenic high-risk populations, 618–619
Irritable bowel syndrome
  food-borne infections and, 601

L

Lactoferrin
  stool
    in food-borne illness diagnosis, 546
Listeriosis
  food-borne infections and, 607–608
Loperamide
  in food-borne illness management, 563

M

Micronutrients
  in food-borne illness management, 560–561
N
Neurologic dysfunction
   food-borne infections and, 607–608
Norovirus (NoV). See Human norovirus (NoV)
NoV. See Human norovirus (NoV)

O
Opiate(s)
   in food-borne illness management, 563
Oral rehydration therapy (ORT)
   in food-borne illness management, 560
ORT. See Oral rehydration therapy (ORT)
Ova and parasite examination
   in food-borne illness diagnosis, 550–551

P
Peanut butter
   Salmonella and
      in food-borne diseases, 525–526
Peritoneal dialysis
   infections related to
      in HUS patients, 590–591
Peritonitis
   dialysis-associated
      treatment of
         in HUS patients, 591
PFGE. See Pulsed-field gel electrophoresis (PFGE)
Pregnancy
   immune suppression related to
      food-borne diseases and, 624
Probiotics
   in food-borne illness management, 562
Pulsed-field gel electrophoresis (PFGE)
   in food-borne illness diagnosis, 550

R
Reactive arthritis
   food-borne infections and, 606
Renal failure
   food-borne infections and, 608–610
   long-term systemic sequelae secondary to, 609–610

S
Salmonella spp.
   food-borne illnesses related to
      treatment of
antimicrobial agents in, 565–567
multidrug-resistant
  ground turkey and
    in food-borne diseases, 525
peanut butter and
  in food-borne diseases, 525–526
Shiga toxin (Stx)
  properties of, 635
Shiga toxin (Stx)–induced disease, 632–633
Shiga toxin–producing *Escherichia coli* (STEC), 631–649
  EHEC and, 632
    German outbreak of (2011)
      HUS and, 638
        hybrid pathogen associated with, 638–640
        pathogenesis of, 638
        treatment of, 640–642
Shiga toxin–producing *Escherichia coli* (STEC) infections
  background of, 578
    *Escherichia coli* 0157:H7 vs. non-0157:H7 EHEC
      diagnosis and comparative outcomes, 578–583
    introduction, 577–578
    nomenclature associated with, 578
    pathogenesis of, 578
    treatment of, 577–597
*Shigella* spp.
  food-borne illnesses related to
    treatment of
      antimicrobial agents in, 567
STEC. See Shiga toxin–producing *Escherichia coli* (STEC)
Stool(s)
  white blood cells in
    in food-borne illness diagnosis, 546
Stool culture
  in food-borne illness diagnosis, 546–548
Stool lactoferrin
  in food-borne illness diagnosis, 546

T
Toxin(s)
  A
    *Clostridium difficile* and, 677
  B
    *Clostridium difficile* and, 677
      in food-borne illness diagnosis
        detection of, 549–550
Toxoplasmosis
  food-borne infections and, 608
Translocation of pathogens
  as physiologic defense against food-borne diseases in iatrogenic high-risk populations, 620
Transplant recipients
   food-borne diseases in, 623–624

V
Vaccine(s)
   against human NoV, 661–667
      live vectored vaccine candidates, 666–667
      need for development, 661–663
      protein-based subunit vaccine candidates, 663–666

W
Water-borne pathogens
   treatment of, 568–569
White blood cells in stool
   in food-borne illness diagnosis, 546

Z
Zoonosis
   Clostridium difficile and, 679